ArticleNature communications2023
Mechano-boosting nanomedicine antitumour efficacy by blocking the reticuloendothelial system with stiff nanogels.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery.Nature communications · 2024Pooled it
- Sonogenetic flexible nanogels enabling enhanced calcium overload-induced immunogenic cell death for tumor immunotherapy.Bioactive materials · 2026Article
- Micro/Nanorobots (MNRs) at the Intersection of Mechanobiology and Artificial Intelligence: An Emerging Frontier for Precision Nanomedicine.ACS nano medicine · 2026Review
- Plaque-Hepatic Targeting Nanotherapy Disrupts the PCSK9-LOX-1 Axis to Suppress oxLDL in Atherosclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A flexibility-driven delivery strategy for cationic liposomes to enhance tumor penetration and promote membrane fusion-mediated cellular entry.Materials today. Bio · 2026Article
- Mechano-reprogramming of tumor-associated macrophages by engineering nanogel stiffness for suppression of tumor development.Journal of nanobiotechnology · 2026Article
- Engineered zwitterion-nanodelivery for precision targeting of brain metastases.Nature communications · 2026Article
- Research Progress on Natural Polysaccharide Hydrogels in the Diagnosis and Treatment of Colorectal Cancer.Gels (Basel, Switzerland) · 2026Review
- Chemokine-Guided Biomimetic Mn/Ce Nanozymes for Immunomodulation and Cardioprotection in Doxorubicin-Induced Cardiomyopathy.Advanced healthcare materials · 2026Article
- Soft cell-derived hybrid microparticles with platelet decoys for enhanced cancer chemotherapy.Acta pharmaceutica Sinica. B · 2026Article
- Safety, Distribution, and Pharmacokinetics of Biodegradable P(AAm-co-MAA) Nanogels Following Systemic Administration in Mice.Journal of biomedical materials research. Part A · 2026Article
- Dual-stiffness nanoparticles for compartment-specific drug delivery in stroke.Nature communications · 2026Article
- Oral Rhizoma Coptis Alkaloids Nanoparticle for Treating Diabetes Through Regulating PI3K/Akt Pathways.Pharmaceutics · 2026Article
- Rational design of rigid mRNA folding architecture to enhance intracellular processing and protein production.Nature nanotechnology · 2026Article
- Tuning mechanical softness as a design principle in drug delivery: A biomechanical perspective.Acta pharmaceutica Sinica. B · 2026Review
- A biohybrid platform integrating bacterial propulsion and photoresponsive nanomedicine for adequate intratumoral drug delivery.Journal of nanobiotechnology · 2026Article
- Engineering combination nanomedicines to overcome cancer resistance.RSC advances · 2026Review
- Article
- Theranostic Nanoparticles in Prostate Cancer: Disrupting Hypoxia-Induced Glycolysis by Targeting Hypoxia-Inducible Factor-1 Alpha and Downstream Metabolites.Cancer medicine · 2026Review
- Multifunctional Graphene Oxide Quantum Dot Nanoformulation with Key Immunomodulation for Effective Anticancer Therapy in Mice Model.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanomedicine has been developed for cancer therapy over several decades, while rapid clearance from blood circulation by reticuloendothelial system (RES) severely limits nanomedicine antitumour efficacy. We design a series of nanogels with distinctive stiffness and investigate how nanogel mechanical properties could be leveraged to overcome RES. Stiff nanogels are injected preferentially to abrogate uptake capacity of macrophages and temporarily block RES, relying on inhibition of clathrin and prolonged liver retention. Afterwards, soft nanogels deliver doxorubicin (DOX) with excellent efficiency, reflected in high tumour accumulation, deep tumour penetration and outstanding antitumour efficacy. In this work, we combine the advantage of stiff nanogels in RES-blockade with the superiority of soft nanogels in drug delivery leads to the optimum tumour inhibition effect, which is defined as mechano-boosting antitumour strategy. Clinical implications of stiffness-dependent RES-blockade are also confirmed by promoting antitumour efficacy of commercialized nanomedicines, such as Doxil and Abraxane.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.